Breast Cancer Research and Treatment

, Volume 111, Issue 1, pp 93–101 | Cite as

Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer

  • Mary A. Bewick
  • Michael S. C. Conlon
  • Robert M. Lafrenie
Preclinical Study


Treatments for metastatic breast cancer (MBC) are primarily palliative with variable efficacy and outcomes may be influenced by individual differences in drug metabolism. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in genes involved in drug metabolism with progression free survival (PFS) and breast cancer specific survival (BCSS) in 95 patients with MBC that received high dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT). SNPs in the SOD2 (SOD2-01, Val16Ala), MPO (MPO-02, -463 promoter variant) and GSTP1 [GSTP1-01 (Ile105Val), GSTP1-02 (Ala114Val)] genes were examined in DNA isolated from cryopreserved blood products using genotyping assays. Survival was analysed using Cox proportional hazard models and Kaplan–Meier estimates. Patients with the SOD2-01 (TT) genotype had increased risk of disease progression [hazard ratio (HR): 2.52; 95% confidence interval (CI), 1.31–4.85] and breast cancer specific death (HR: 1.92; 95% CI: 1.03–3.57). Risks were increased for patients with both SOD2-01 (TT) and GSTP1-01 (GG or AG) genotypes (HR for disease progression: 2.57, 95% CI: 1.32–5.00 and HR for breast cancer specific death: 2.27; 95% CI: 1.18–4.34). In multivariable analysis, the combined genotype group of SOD2-01 and GSTP1-01 was an independent predictor of PFS and BCSS. HRs progressively increased with increasing number of genotypes associated with worse survival, with p (trend) of 0.005 and 0.006 for PFS and BCSS, respectively. These results suggest that SNPs in genes involved in drug metabolism may influence survival outcome for patients with MBC receiving HDC and ASCT.


Drug metabolism Metastatic breast cancer Polymorphisms Survival 



We would like to thank the Northern Cancer Research Foundation for their generous support of this research. Also special thanks to Colleen Langdon, Sue Gerard and Jane Vanderklift for their expertise and assistance.


  1. 1.
    Hayes JD, Strange RC (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154–166PubMedCrossRefGoogle Scholar
  2. 2.
    Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC (2004) MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett 214:69–79PubMedCrossRefGoogle Scholar
  3. 3.
    Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, Ambrosone CB (2004) Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol 93:615–620PubMedCrossRefGoogle Scholar
  4. 4.
    Yang G, Shu XO, Ruan ZX, Cai QY, Jin F, Gao YT, Zheng W (2005) Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103:52–58PubMedCrossRefGoogle Scholar
  5. 5.
    Ambrosone CB, Ahn J, Singh KK, Rezaishiraz H, Furberg H, Sweeney C, Coles B, Trovato A (2005) Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res 65:1105–1111PubMedGoogle Scholar
  6. 6.
    Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H (2006) Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100:330–337PubMedCrossRefGoogle Scholar
  7. 7.
    Conklin KA (2004) Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3:294–300PubMedCrossRefGoogle Scholar
  8. 8.
    Weijl NI, Cleton FJ, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209–240PubMedCrossRefGoogle Scholar
  9. 9.
    La TF, Orlando A, Silipigni A, Giacobello T, Pergolizzi S, Aragona M (1997) Increase of oxygen free radicals and their derivatives in chemo- and radiation treated neoplasm patients. Minerva Med 88:121–126Google Scholar
  10. 10.
    Lopez-Lazaro M (2006) Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett 252:1–8PubMedCrossRefGoogle Scholar
  11. 11.
    Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B, Goldwasser F (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41–48PubMedCrossRefGoogle Scholar
  12. 12.
    Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65:8455–8460PubMedCrossRefGoogle Scholar
  13. 13.
    Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D, Degoul F (2005) The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 15:311–319PubMedCrossRefGoogle Scholar
  14. 14.
    Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG (1999) Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59:602–606PubMedGoogle Scholar
  15. 15.
    Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Uusitupa M, Hirvonen A (2001) Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 22:827–829PubMedCrossRefGoogle Scholar
  16. 16.
    Stoehlmacher J, Ingles SA, Park DJ, Zhang W, Lenz HJ (2002) The -9Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma. Oncol Rep 9:235–238PubMedGoogle Scholar
  17. 17.
    Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D (2003) Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14:513–518PubMedCrossRefGoogle Scholar
  18. 18.
    Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelatti U, Placidi D, Carta A, Hautefeuille A, Porru S (2004) Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 25:973–978PubMedCrossRefGoogle Scholar
  19. 19.
    Pattison DI, Davies MJ (2006) Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem 13:3271–3290PubMedCrossRefGoogle Scholar
  20. 20.
    Klebanoff SJ (1999) Myeloperoxidase. Proc Assoc Am Physicians 111:383–389PubMedGoogle Scholar
  21. 21.
    Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K et al (2002) Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer 102:530–535PubMedCrossRefGoogle Scholar
  22. 22.
    Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF (1996) An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271:14412–14420PubMedCrossRefGoogle Scholar
  23. 23.
    Wu X, Schabath MB, Spitz MR (2003) Myeloperoxidase promoter region polymorphism and lung cancer risk. Methods Mol Med 75:121–133PubMedGoogle Scholar
  24. 24.
    Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, Benhamou S (2002) Point: myeloperoxidase -463G –> a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 11:1550–1554PubMedGoogle Scholar
  25. 25.
    Matsuo K, Hamajima N, Shinoda M, Hatooka S, Inoue M, Takezaki T, Onda H, Tajima K (2001) Possible risk reduction in esophageal cancer associated with MPO -463 A allele. J Epidemiol 11:109–114PubMedGoogle Scholar
  26. 26.
    Hayes JD, McLellan LI (1999) Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 31:273–300PubMedCrossRefGoogle Scholar
  27. 27.
    Bosch TM, Meijerman I, Beijnen JH, Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285PubMedCrossRefGoogle Scholar
  28. 28.
    Gate L, Tew KD (2001) Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 5:477–489PubMedCrossRefGoogle Scholar
  29. 29.
    McIlwain CC, Townsend DM, Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25:1639–1648PubMedCrossRefGoogle Scholar
  30. 30.
    Pandya U, Srivastava SK, Singhal SS, Pal A, Awasthi S, Zimniak P, Awasthi YC, Singh SV (2000) Activity of allelic variants of Pi class human glutathione S-transferase toward chlorambucil. Biochem Biophys Res Commun 278:258–262PubMedCrossRefGoogle Scholar
  31. 31.
    Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, Singh SV (1998) Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c]phenanthrene and benzo[g]chrysene. Cancer Res 58:5340–5343PubMedGoogle Scholar
  32. 32.
    Ishimoto TM, li-Osman F (2002) Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 12:543–553PubMedCrossRefGoogle Scholar
  33. 33.
    Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB (2000) Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60:5621–5624PubMedGoogle Scholar
  34. 34.
    Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ, Dring AM, Fenton JA, Child JA, Allan JM et al (2003) Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 102:2345–2350PubMedCrossRefGoogle Scholar
  35. 35.
    Lee JM, Wu MT, Lee YC, Yang SY, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee CJ, Chen CJ (2005) Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 11:4749–4753PubMedCrossRefGoogle Scholar
  36. 36.
    Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645–5651PubMedCrossRefGoogle Scholar
  37. 37.
    National Cancer Institute (2007) Cancer genome anatomy project. SNP500 cancer database.
  38. 38.
    Brockstedt U, Krajinovic M, Richer C, Mathonnet G, Sinnett D, Pfau W, Labuda D (2002) Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs). Mutat Res 516:41–47PubMedGoogle Scholar
  39. 39.
    Ambrosone CB, Sweeney C, Coles BF, Thompson PA, McClure GY, Korourian S, Fares MY, Stone A, Kadlubar FF, Hutchins LF (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61:7130–7135PubMedGoogle Scholar
  40. 40.
    Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL, Vaughan TL (2003) Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12:527–533PubMedGoogle Scholar
  41. 41.
    Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun WJ, Kim WJ (2005) Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65:70–75PubMedCrossRefGoogle Scholar
  42. 42.
    Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients. Br J Cancer 94:281–286PubMedCrossRefGoogle Scholar
  43. 43.
    Gonlugur U, Pinarbasi H, Gonlugur TE, Silig Y (2006) The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome. Cancer Invest 24:497–501PubMedCrossRefGoogle Scholar
  44. 44.
    Barragan E, Collado M, Cervera J, Martin G, Bolufer P, Roman J, Sanz MA (2006) The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 31:947–953PubMedCrossRefGoogle Scholar
  45. 45.
    Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942PubMedGoogle Scholar
  46. 46.
    Sun XF, Ahmadi A, Arbman G, Wallin A, Asklid D, Zhang H (2005) Polymorphisms in sulfotransferase 1A1 and glutathione S-transferase P1 genes in relation to colorectal cancer risk and patients’ survival. World J Gastroenterol 11:6875–6879PubMedGoogle Scholar
  47. 47.
    Holley SL, Rajagopal R, Hoban PR, Deakin M, Fawole AS, Elder JB, Elder J, Smith V, Strange RC, Fryer AA (2006) Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int J Oncol 28:231–236PubMedGoogle Scholar
  48. 48.
    Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah PP (2002) Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 62:3052–3057PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2007

Authors and Affiliations

  • Mary A. Bewick
    • 1
  • Michael S. C. Conlon
    • 1
  • Robert M. Lafrenie
    • 1
    • 2
  1. 1.Sudbury Regional Hospital, Regional Cancer CenterSudburyCanada
  2. 2.Northern Ontario School of MedicineSudburyCanada

Personalised recommendations